NCT03252340View on ClinicalTrials.gov

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

August 17, 2022

Study Completion Date

September 27, 2022

Conditions
Atopic Dermatitis
Interventions
DRUG

ADSTEM Inj.

"1. ADSTEM Inj. 1.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~2. ADSTEM Inj. 3.0x10\^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."

Trial Locations (1)

Unknown

Chungnam National University Hospital, Daejeon

All Listed Sponsors
lead

EHL Bio Co., Ltd.

INDUSTRY

NCT03252340 - Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis | Biotech Hunter | Biotech Hunter